España
Acceder

Farmas USA

136K respuestas
Farmas USA
Farmas USA
Página
15.255 / 17.075
#122033

Re: Farmas USA

Top 25
anaramos
MRNA


  • Moderna's (NASDAQ:MRNA) experimental vaccine, mRNA-1273, is currently being tested in early-stage trial by the U.S. National Institutes of Health, with mid-stage trials set for Q2.
  • The 10-year collaboration agreement will see the companies produce up to a billion vaccine doses per year at Lonza U.S. (OTCPK:LZAGY), and would cover additional products in the future.
  • In April, Moderna scored $483M in U.S. federal funding to accelerate development of mRNA-1273

«Después de nada, o después de todo/ supe que todo no era más que nada.»

#122034

Re: Farmas USA

Top 25
anaramos
GILD

  • beats by $0.12; GAAP EPS of $1.22 misses by $0.03.
  • Revenue of $5.55B (+5.1% Y/Y) beats by $110M.
  • Gilead Sciences (NASDAQ:GILD) Q1 results:
  • Revenues: $5,548M (+5.1%); product sales: $5,467M (+5.1%); HIV: $4,134M (+14.3%).
  • $200M in sales resulted from customer inventory builds to satisfy 90-day prescriptions during the pandemic, expected to reverse in the coming quarters.
  • Top sellers: Biktarvy: $1,693M (+113.5%); Genvoya: $824M (-18.8%); Truvada: $406M (-33.0%); Odefsey: $409M (+3.0%); Descovy: $458M (+33.9%); Yescarta: $140M (+45.8%).
  • Net income: $1,551M (-21.5%); non-GAAP net income: $2,139M (flat); EPS: $1.22 (-20.8%); non-GAAP EPS: $1.68 (+0.6%).
  • 140K courses of remdesivir will be manufactured by the end of May, more than 1M by year-end.
  • 2020 guidance: Pandemic disruptions expected to negatively impact operations, but the specifics are uncertain at present.


  • Gilead's (NASDAQ:GILD) Q1 results were unsurprisingly overshadowed by discussions on remdesivir, Barclays analyst Carter Gould writes in a note to clients.
  • Disclosures of up to $1B in remdesivir spend this year and the lack of any meaningful color on its economics will likely weigh on shares near term.
  • Importantly, donating 1.5M doses also delays any clarity on pricing strategy for at least the next month.
  • GILD is appropriately reading the room. But the market "has priced in such an optimistic view of remdesivir’s commercial potential that we suspect the near-term uncertainty will weigh on shares notably."
  • Upcoming data from the NIAID and SIMPLE studies over the next few weeks should provide further characterization of remdesivir’s profile.
  • Retains Sell rating. Price target of $67 from $62 implies 24% downside.
  • Shares are -3.5% on light premarket volume.

«Después de nada, o después de todo/ supe que todo no era más que nada.»

#122040

Re: Farmas USA
Buenos días a todos. Maravilloso día de paseo, se necesitaba...
A que te refieres con redondear el techo? 
A cerrar el Gap del gráfico anterior, testeando de nuevo la Mm200, antes de enfilar la bajada?? 
Se habla de...
Pfizer (PFE)
Te puede interesar...
  1. Grifols, una nueva esperanza.
  2. Análisis técnico. . Semana del 12-16 Mayo.Apetito por riesgo.
  3. Bolsas eufóricas tras acuerdo arancelario pero los bonos insisten…
  4. Deuda USA insostenible y en niveles críticos, bolsas celebrando algo
  5. ¿Pánico u oportunidad de inversión? Tú eliges…
  1. Grifols, una nueva esperanza.
  2. Análisis técnico. . Semana del 12-16 Mayo.Apetito por riesgo.
  3. EEUU y China acuerdan una pausa en los aranceles: ¿Trump se baja los pantalones?
  4. Tesis de Duolingo - Mi Nueva Posición en Cartera
  5. Deuda USA insostenible y en niveles críticos, bolsas celebrando algo